| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3850891 | American Journal of Kidney Diseases | 2010 | 11 Pages |
Abstract
Pharmacokinetic assessment showed increased clearance of adalimumab in patients with resistant primary FSGS and validated the need to evaluate the disposition of novel therapies for this disease to define appropriate dosing regimens. The study provides a rationale to evaluate the efficacy of adalimumab as an antifibrotic agent for resistant FSGS in phase 2/3 clinical trials.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Melanie S. PharmD, Debbie S. MD, MSPH, Leslie RN, CPNP, Jacqueline BS, J. Charles MD, Suzanne RN, Cynthia MD, Virginia MD, Allison MD, Agnes B. MD, Jeffrey B. MD, Daniel MD, FRCPC, Howard MD,